Research programme: peptides - APIM Therapeutics

Drug Profile

Research programme: peptides - APIM Therapeutics

Alternative Names: ATX 101

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator APIM Therapeutics; Norwegian university of science and technology
  • Class Peptides
  • Mechanism of Action Proliferating cell nuclear antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Bladder cancer; Breast cancer; Glioblastoma; Multiple myeloma; Prostate cancer

Most Recent Events

  • 07 Oct 2016 Preclinical trials in Bladder cancer in Norway (Intravesicular)
  • 07 Oct 2016 Preclinical trials in Glioblastoma in Norway (unspecified route)
  • 07 Oct 2016 APIM Therapeutics has patent protection for peptides comprising APIM-motif in USA, Japan, Australia and Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top